INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies

[1]  Satoshi Teramukai,et al.  A Bayesian basket trial design that borrows information across strata based on the similarity between the posterior distributions of the response probability , 2019, Biometrical journal. Biometrische Zeitschrift.

[2]  David T. W. Jones,et al.  Brainstem biopsy in pediatric diffuse intrinsic pontine glioma in the era of precision medicine: the INFORM study experience. , 2019, European journal of cancer.

[3]  Karl Broich,et al.  Master protocols in clinical trials: a universal Swiss Army knife? , 2019, The Lancet. Oncology.

[4]  Annette Kopp-Schneider,et al.  Monitoring futility and efficacy in phase II trials with Bayesian posterior distributions—A calibration approach , 2018, Biometrical journal. Biometrische Zeitschrift.

[5]  B. Chang,et al.  ADVL1513: Results of a phase 1 trial of entinostat, an oral histone deacetylase inhibitor, in pediatric patients with recurrent or refractory solid tumors. , 2018 .

[6]  P. Danaher,et al.  Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with melanoma progressing on or after a PD-1/L1 blocking antibody. , 2018 .

[7]  P. Jänne,et al.  Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with non-small cell lung cancer (NSCLC) previously treated with anti-PD-(L)1 therapy. , 2018 .

[8]  G. Long,et al.  Patterns of Response and Progression to Immunotherapy. , 2018, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[9]  David T. W. Jones,et al.  DNA methylation-based classification of central nervous system tumours , 2018, Nature.

[10]  K. Norga,et al.  Joint adolescent–adult early phase clinical trials to improve access to new drugs for adolescents with cancer: proposals from the multi-stakeholder platform—ACCELERATE , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  Publisher's Note , 2018, Anaesthesia.

[12]  P. Stephens,et al.  Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers , 2017, Molecular Cancer Therapeutics.

[13]  Susan M. Chang,et al.  Response Assessment in Neuro-Oncology Clinical Trials. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Nakul M. Shah,et al.  DNMT and HDAC inhibitors induce cryptic transcription start sites encoded in long terminal repeats , 2017, Nature Genetics.

[15]  K. Davis,et al.  ADVL1412: Initial results of a phase I/II study of nivolumab and ipilimumab in pediatric patients with relapsed/refractory solid tumors—A COG study. , 2017 .

[16]  Robert Ford,et al.  iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. , 2017, The Lancet. Oncology.

[17]  D. Merico,et al.  Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  S. Gettinger,et al.  Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  David T. W. Jones,et al.  Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study. , 2016, European journal of cancer.

[20]  D. Felsher,et al.  MYC regulates the antitumor immune response through CD47 and PD-L1 , 2016, Science.

[21]  J. Olson,et al.  HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC-Driven Medulloblastoma. , 2016, Cancer cell.

[22]  E. Haura,et al.  HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma , 2016, Clinical Cancer Research.

[23]  Raymond Y Huang,et al.  Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. , 2015, The Lancet. Oncology.

[24]  C. Swanton,et al.  The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  M. Kool,et al.  Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma , 2015, Acta neuropathologica communications.

[26]  B. Geoerger,et al.  Patients in Pediatric Phase I and Early Phase II Clinical Oncology Trials at Gustave Roussy: A 13-Year Center Experience , 2015, Journal of pediatric hematology/oncology.

[27]  K. Kinzler,et al.  Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells , 2014, Journal of Immunotherapy for Cancer.

[28]  G. Leverger,et al.  The prognostic significance of early treatment response in pediatric relapsed acute myeloid leukemia: results of the international study Relapsed AML 2001/01 , 2014, Haematologica.

[29]  G. Adema,et al.  HDAC inhibitors and immunotherapy; a double edged sword? , 2014, Oncotarget.

[30]  F. Gilles,et al.  A retrospective analysis of recurrent intracranial ependymoma , 2014, Pediatric blood & cancer.

[31]  Yoon-Jae Cho,et al.  HIGH-THROUGHPUT DRUG SCREENING IDENTIFIES HDAC INHIBITORS AS CANDIDATE THERAPEUTICS FOR MYC-DRIVEN MEDULLOBLASTOMA , 2014 .

[32]  Jennifer Couzin-Frankel,et al.  Breakthrough of the year 2013. Cancer immunotherapy. , 2013, Science.

[33]  David T. W. Jones,et al.  Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. , 2013, The Lancet. Oncology.

[34]  D. Berry,et al.  Bayesian hierarchical modeling of patient subpopulations: Efficient designs of Phase II oncology clinical trials , 2013, Clinical trials.

[35]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[36]  C. Anasetti,et al.  LBH589 enhances T cell activation in vivo and accelerates graft-versus-host disease in mice. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[37]  J. Gil,et al.  Histone deacetylase inhibition induces apoptosis and autophagy in human neuroblastoma cells. , 2012, Cancer letters.

[38]  L. Ellis,et al.  Class I Histone Deacetylase Inhibitor Entinostat Suppresses Regulatory T Cells and Enhances Immunotherapies in Renal and Prostate Cancer Models , 2012, PloS one.

[39]  T. MacDonald,et al.  Treatment of high-grade glioma in children and adolescents. , 2011, Neuro-oncology.

[40]  U. Dirksen,et al.  Risk of recurrence and survival after relapse in patients with Ewing sarcoma , 2011, Pediatric blood & cancer.

[41]  F. Berthold,et al.  Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  B. Carlin,et al.  Bayesian Adaptive Methods for Clinical Trials , 2010 .

[43]  R. Barr,et al.  Childhood Atypical Teratoid Rhabdoid Tumor of the Central Nervous System: A Meta-Analysis of Observational Studies , 2009, Journal of pediatric hematology/oncology.

[44]  James R. Anderson,et al.  Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  M. Semik,et al.  Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  D. Kennedy.  Breakthrough of the Year , 2004, Science.

[47]  M. Cohen,et al.  Outcomes of treatment of children and adolescents with recurrent non-Hodgkin's lymphoma and Hodgkin's disease with dexamethasone, etoposide, cisplatin, cytarabine, and l-asparaginase, maintenance chemotherapy, and transplantation: Children's Cancer Group Study CCG-5912. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  L V Rubinstein,et al.  A comparison of two phase I trial designs. , 1994, Statistics in medicine.

[49]  Trevor J Pugh,et al.  Mutational heterogeneity in cancer and the search for new cancer genes , 2014 .

[50]  G. Henze,et al.  Outcome of children and adolescents with relapsed acute lymphoblastic leukaemia and non-response to salvage protocol therapy: a retrospective analysis of the ALL-REZ BFM Study Group. , 2011, European journal of cancer.